A new experimental cancer treatment has sparked global excitement after doctors reported that tumours shrank or disappeared in dozens of patients, with some seeing their cancer eradicated entirely.
WEBDESK – MediaBites News – Source: Malay Mail
An experimental cancer jab being tested across 11 countries has delivered what researchers are calling some of the strongest results ever seen in patients whose disease had stopped responding to conventional treatments.
The drug, known as amivantamab, was trialled on patients with advanced cancers that had either spread or returned after failing to respond to chemotherapy and immunotherapy.
According to findings set to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the treatment produced remarkable responses among patients with head and neck cancer, one of the world’s most common forms of the disease.
In the international study, 102 patients received the experimental jab. Researchers reported that tumours shrank or disappeared in 43 patients, while 15 patients experienced complete tumour eradication.
Experts described the results as highly encouraging, particularly because the patients involved had exhausted many of the standard treatment options available to them.
“These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy,” said Professor Kevin Harrington of the Institute of Cancer Research in London and consultant oncologist at the Royal Marsden NHS Foundation Trust.
Researchers also reported promising results among lung cancer patients participating in related studies, raising hopes that the treatment could have broader applications across multiple cancer types.
Amivantamab is designed to attack cancer through multiple mechanisms simultaneously, helping the immune system identify and destroy cancer cells while targeting key pathways that allow tumours to grow and spread.
The drug was developed by pharmaceutical giant Johnson & Johnson and is currently being evaluated in approximately 60 clinical trials worldwide.
While experts caution that larger studies and longer follow-up periods are still needed before the treatment can be considered a cure, the early findings are being viewed as a significant step forward in cancer research.
Cancer remains one of the leading causes of death globally, with millions of new cases diagnosed every year. Scientists have increasingly focused on precision medicines and immune-based therapies in an effort to improve survival rates and reduce the side effects associated with traditional treatments.
The latest results have generated optimism among oncologists, who say the therapy could potentially offer a new lifeline for patients with advanced cancers that no longer respond to existing treatments.
Researchers are expected to continue monitoring trial participants to determine how long the responses last and whether the treatment can improve long-term survival outcomes.
If future studies confirm the findings, amivantamab could become one of the most important advances in cancer treatment in recent years, offering renewed hope to patients facing some of the most difficult forms of the disease.
